Search Results

The in-vitro measurement of anticardiolipin antibodies in human serum, as an aid in the diagnosis of antiphospholipid syndrome (APS).

Not Found

The provided document is a 510(k) premarket notification letter from the FDA for a device called "Anticardiolipin IgM Screen EIA Kit." This document does not contain details about acceptance criteria or a study proving the device meets those criteria, nor does it describe AI-related performance studies.

The letter primarily:

• Confirms receipt and review of the 510(k) submission.
• States that the device is substantially equivalent to legally marketed predicate devices.
• Outlines post-market regulatory requirements and general controls provisions of the Act.
• Provides contact information for further inquiries.
• Mentions the device's indications for use (in the enclosure).

Therefore, I cannot extract the requested information regarding acceptance criteria, study details, sample sizes, ground truth establishment, expert qualifications, adjudication methods, or AI-related comparative effectiveness studies from the provided text.

Ask a specific question about this device